Kyn Therapeutics Revenue and Competitors

Kyn Therapeutics is a clinical-stage biotechnology company specializing in the development of cancer therapeutics targeting well-characterized immuno-metabolic pathways. Based in Boston, Massachusetts, we launched in December 2017 with $49M Series A funding provided by OrbiMed Advisors and Atlas Venture. Kyn is working toward bringing breakthrough therapies to patients suffering from cancer, particularly those who do not benefit from current treatments like checkpoint inhibitors. Kyn is leveraging years of pre-clinical and clinical research to explore the full potential of immuno-metabolic targets to enhance anti-tumor immune responses. Led by a strong leadership team with deep expertise in translational and clinical development and an experienced Board of Directors, Kyn is building a pipeline of programs that have the potential, either as monotherapies or as a powerful adjunct to modern immunotherapies, to overcome broad immunosuppression by modulating both the innate and adaptive immune systems.